RPRX: financial statements from SEC — TradeAlmanac

RPRX

Royalty Pharma plc: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	631m	609m	579m	568m	565m	537m
Research and development	40m	51m	301m	51m	500,000	500,000
Selling, general and administrative	159m	119m	180m	111m	57m	55m
Operating expenses	68m	182m	369m	34m	−170m	268m
Operating income	563m	427m	210m	534m	735m	270m
Pre-tax income	468m	444m	91m	433m	806m	194m
Income tax	0	0	0	0	0	0
Net income	295m	288m	30m	238m	544m	102m
Earnings per share	0.67	0.67	0.07	0.55	1.22	0.23
Earnings per share, diluted	0.67	0.67	0.07	0.55	1.21	0.23
Weighted average shares	437m	432m	424m	435m	448m	451m
Weighted average shares, diluted	557m	560m	562m	578m	593m	597m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	586m	619m	939m	632m	1.09bn	929m	950m	1.76bn
Current assets	1.43bn	1.53bn	1.85bn

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	718m	596m
Investing cash flow	−478m	504m
Share buybacks	50m	709m
Financing cash flow	−273m	−941m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)